title: French multicenter trial of anistreplase versus heparin in acute myocardial infarction.
abstract: Eighty-four patients aged less than 71 years with less than 4-hour duration acute myocardial infarction (AMI) were randomized in a multicenter study to 30 U anistreplase or heparin (single injection of 6500 IU followed by 1000 IU/hr). Early reperfusion was assessed from ECG changes (50% of sum ST decrease 2 hours postdosing) and the CK release profile (CK peak less than 16 hours after onset of symptoms, CK slope greater than 10%/hr). Reperfusion rates in patients meeting at least two criteria of reperfusion were 62.5% on anistreplase versus 27.5% on heparin. On delayed angiogram (13.7 +/- 3.4 days), patency rates were 66% with anistreplase versus 47% (NS) with heparin in 76 patients. Global LVF was similar in both groups. With anistreplase, the mean lowest fibrinogen level was 0.43 +/- 0.55 g/l, plasminogen was 20 +/- 9%, and the highest F.D.P. was 1447 +/- 548 micrograms/ml. All values recovered by hour 48. In-hospital and 1-year follow-up mortality was 7.2% (three patients) with anistreplase versus 10.2% (four patients) with heparin. Bleeding occurred in 9.7% and 5.1% of the patients (NS), respectively. No intracranial hemorrhage occurred. Thus, with combined clinical criteria or reperfusion, anistreplase is twice as efficient as heparin, has a good tolerance, and is easy to use as a single injection.
authors.affiliation: Centre Hospitalier Gilles de Corbeil, Corbeil-Essonnes, France.
authors.forename: H
authors.initials: H
authors.lastname: Lardoux
authors.forename: Y
authors.initials: Y
authors.lastname: Louvard
authors.forename: D
authors.initials: D
authors.lastname: de Vernejoul
authors.forename: C
authors.initials: C
authors.lastname: Picot
authors.forename: M
authors.initials: M
authors.lastname: Baudet
authors.forename: M
authors.initials: M
authors.lastname: Hiltgen
authors.forename: M
authors.initials: M
authors.lastname: Houplon
authors.forename: J
authors.initials: J
authors.lastname: Ponsonnaille
authors.forename: M
authors.initials: M
authors.lastname: Richard
authors.forename: R
authors.initials: R
authors.lastname: Luccioni
mesh_terms: D016255:Anistreplase / Q000009:adverse effects / Q000627:therapeutic use*; D017023:Coronary Angiography; D005260:Female; D005602:France; D006403:Hematologic Tests; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D015425:Myocardial Reperfusion; D011446:Prospective Studies
chemical_list: D016255:Anistreplase; D006493:Heparin